Terms: = Lung cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Treatment
103 results:
1. Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for cancer Immunotherapy.
Geng Q; Jiao P
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257366
[TBL] [Abstract] [Full Text] [Related]
2. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
[TBL] [Abstract] [Full Text] [Related]
3. [Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy].
Sotnikova TN; Polushkina TV; Danilova NV
Arkh Patol; 2023; 85(6):70-75. PubMed ID: 38010641
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell lung cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Dhamelincourt E; Descourt R; Rousseau-Bussac G; Doubre H; Decroisette C; Demontrond P; Le Garff G; Falchero L; Huchot E; Vieillot S; Corre R; Kazulinski L; Bizieux A; Bigay-Gamé L; Morel H; Molinier O; Chouaïd C; Guisier F
Target Oncol; 2023 Nov; 18(6):905-914. PubMed ID: 37966566
[TBL] [Abstract] [Full Text] [Related]
5. Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.
Stiefel J; Kushner BH; Roberts SS; Iglesias-Cardenas F; Kramer K; Modak S
JCO Precis Oncol; 2023 Aug; 7():e2300138. PubMed ID: 37561984
[TBL] [Abstract] [Full Text] [Related]
6. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell lung cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F; Redrado M; Houry M; Hastings K; Molero-Abraham M; Lozano T; Solorzano JL; Sanz-Ortega J; Adradas V; Amat R; Redin E; Leon S; Legarra N; Garcia J; Serrano D; Valencia K; Robles-Oteiza C; Foggetti G; Otegui N; Felip E; Lasarte JJ; Paz-Ares L; Zugazagoitia J; Politi K; Montuenga L; Calvo A
Cancer Res; 2023 Aug; 83(15):2513-2526. PubMed ID: 37311042
[TBL] [Abstract] [Full Text] [Related]
7. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.
Rocha P; Rodrigo M; Moliner L; Menendez S; Masfarré L; Navarro N; Del Rey-Vergara R; Galindo-Campos M; Taus Á; Giner M; Sanchez I; Rodríguez-Fuster A; Aguiló R; Chalela R; Sánchez-Font A; Belda J; Curull V; Pijuan L; Casadevall D; Clavé S; Bellosillo B; Perera-Bel J; Comerma L; Arriola E
Lung Cancer; 2023 Jul; 181():107257. PubMed ID: 37263182
[TBL] [Abstract] [Full Text] [Related]
8. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.
Raza A; Mohsen R; Kanbour A; Zar Gul AR; Philip A; Vijayakumar S; Hydrose S; Prabhu KS; Al-Suwaidi AK; Inchakalody VP; Merhi M; Abo El-Ella DM; Tauro MA; Akbar S; Al-Bozom I; Abualainin W; Al-Abdulla R; Sirriya SA; Hassnad S; Uddin S; Mohamed Ibrahim MI; Al Homsi U; Demime S
Front Immunol; 2023; 14():1157100. PubMed ID: 37256148
[TBL] [Abstract] [Full Text] [Related]
9. Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer.
Sandström Gerdtsson A; Knulst M; Botling J; Mezheyeuski A; Micke P; Ek S
Oncoimmunology; 2023; 12(1):2206725. PubMed ID: 37139184
[TBL] [Abstract] [Full Text] [Related]
10. Characterization of Viscum album L. Effect on Immune Escape Proteins PD-L1, PD-L2, and MHC-I in the Prostate, Colon, lung, and Breast cancer Cells.
Devi S; Gründemann C; Huber R; Kowarschik S
Complement Med Res; 2023; 30(5):386-392. PubMed ID: 36927644
[TBL] [Abstract] [Full Text] [Related]
11. Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report.
Liu Y; Dong C; He X; Wu P; Shu Y; Chen L
BMC Nephrol; 2023 Mar; 24(1):51. PubMed ID: 36899322
[TBL] [Abstract] [Full Text] [Related]
12. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.
Chintala NK; Choe JK; McGee E; Bellis R; Saini JK; Banerjee S; Moreira AL; Zauderer MG; Adusumilli PS; Rusch VW
Front Immunol; 2023; 14():1112960. PubMed ID: 36875061
[TBL] [Abstract] [Full Text] [Related]
13. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
[TBL] [Abstract] [Full Text] [Related]
14. Construction and Preclinical Evaluation of a
Yao Y; Hou X; Liu S; Liu T; Ren Y; Ma X; Zhang Q; Wang P; Guo Q; Ma X; Yang Z; Zhu H; Li N
Mol Pharm; 2023 Feb; 20(2):1365-1374. PubMed ID: 36579764
[TBL] [Abstract] [Full Text] [Related]
15. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.
Zhu Z; Chen M; Hu G; Pan Z; Han W; Tan W; Zhou Z; Wang M; Mao L; Li X; Sui X; Song L; Xu Y; Song W; Yu Y; Jin Z
Eur Radiol; 2023 Jun; 33(6):3918-3930. PubMed ID: 36515714
[TBL] [Abstract] [Full Text] [Related]
16. Pucotenlimab: First Approval.
Dhillon S
Drugs; 2022 Oct; 82(15):1557-1564. PubMed ID: 36308601
[TBL] [Abstract] [Full Text] [Related]
17. Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell lung cancer.
Wang Q; He Y; Li W; Xu X; Hu Q; Bian Z; Xu A; Tu H; Wu M; Wu X
Front Immunol; 2022; 13():887916. PubMed ID: 35874720
[TBL] [Abstract] [Full Text] [Related]
18. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC.
Fernandez AI; Gavrielatou N; McCann L; Shafi S; Moutafi MK; Martinez-Morilla S; Vathiotis IA; Aung TN; Yaghoobi V; Bai Y; Chan YG; Weidler J; Herbst R; Bates M; Rimm DL
J Thorac Oncol; 2022 Sep; 17(9):1078-1085. PubMed ID: 35764237
[TBL] [Abstract] [Full Text] [Related]
19. treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.
Yang ZY; Jiang CW; Zhang WL; Sun G
J Transl Med; 2022 Jun; 20(1):276. PubMed ID: 35717238
[TBL] [Abstract] [Full Text] [Related]
20. Real-World Patient Characteristics, treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell lung cancer Harboring EGFR Mutations.
He J; Pericone CD; Vanderpoel J
Adv Ther; 2022 Jul; 39(7):3347-3360. PubMed ID: 35674970
[TBL] [Abstract] [Full Text] [Related]
[Next]
